



SPAFID CONNECT

Informazione Regolamentata n. 20166-6-2019	Data/Ora Ricezione 26 Luglio 2019 01:09:14	AIM -Italia/Mercato Alternativo del Capitale
--	--	---

Societa' : Shedir Pharma Group S.p.A.
Identificativo : 121014
Informazione
Regolamentata
Nome utilizzatore : SHEDIRN01 - -
Tipologia : REGEM
Data/Ora Ricezione : 26 Luglio 2019 01:09:14
Data/Ora Inizio : 26 Luglio 2019 07:30:26
Diffusione presunta
Oggetto : Italian patent obtained for Slowpil

Testo del comunicato

Vedi allegato.



Shedir Pharma Group S.p.A.

• PRESS RELEASE •

Italian patent obtained for Slowpil®

The number of group patents rises to 7

Piano di Sorrento (NA), 26th July 2019 – Shedir Pharma Group S.p.A. (“Shedir Pharma Group”, the “Company” or “Issuer”), holding company of the Shedir Pharma group, leader in the healthcare sector (nutraceutical and pharmaceutical) announces its receipt of the Italian patent for **Slowpil®** from the Italian Patent and Trademark Office.

The Slowpil® patented blend, thanks to the combined effects of its main components, is able to prevent body hair regrowth, as well as counteracting dryness of skin. The Slowpil® patent (for which the international patent application has already been filed) allows the group to protect its know how until March 2037.

The Actapil® cosmeceutical spray, containing the patented Slowpil®, has also been subject to a double blind clinically controlled study (including placebos) which demonstrated its effectiveness and safety of use.

With receipt of this patent the number of patents held by the group rises to 7 (please note that the group has a further 50 patents pending in Italy).

Umberto Di Maio, President of Shedir Pharma Group, stated: *“This recognition strengthens further our leadership position in the supplement sector and rewards the constant work of our research team led by Dr Antonio Bagnulo. We will continue to invest in 100% Italian research, which also represents a strong point in foreign markets. We will receive further patent recognition in other strategic therapeutic areas for the group in the coming months. This R&D activity does not end with the award of the patent, but continues through the confirmation of the innovation via the performance and dissemination of clinical studies. At present, of the studies being carried out in collaboration with a selection of Italian Universities, the group has concluded four clinical studies, with four others still in progress.”*

* * *

Shedir Pharma Group S.p.A., is the holding company of the Shedir Pharma group, active in the nutraceutical and pharmaceutical sector and specialised in research, formulation, development and marketing of nutraceutical, dermocosmetic and pharmaceutical products and medical devices. Shedir Pharma S.r.l. Unipersonale, the subsidiary company, is a Borsa Italiana ‘Elite’ company.

The Shedir Pharma group develops and markets functional products in around 15 therapeutic areas (for example cardiology, respiratory, osteoarticular, urological, paediatric, gynaecological, neurological and algological), through a structured network of around 800 exclusive sales agents and directly to top wholesalers who then independently supply pharmacies and parapharmacies. Thanks to the work of its research and development team, and to collaborations with the most important Italian Universities and private research institutions, it is committed to a continuous search for innovation, with the formulation of unique, patent-protected formulations. Product innovation and effectiveness is further supported by published scientific studies. SHEDIRPHARMA® GROUP S.p.A. is also active in the veterinary market with the Shedir® Pet line, a product line developed for the specific needs of animals. The group holds 2 quality certifications that allow constant monitoring through all phases – research, development and marketing of the products.

For further information:

- Shedir Pharma Group S.p.A. ●

Investor Relator

tel: +39 081 19910422

e.mail: investor.relations@shedirpharmagroup.com

- BPER Banca S.p.A. ●

Nominated Adviser

tel: +39 059 2021140

e.mail: shedir@bper.it

Fine Comunicato n.20166-6

Numero di Pagine: 4